Home / About Us / News

Geistlich signs exclusive distribution agreement for OrthoPure® XT

Geistlich Biomaterials Italia is adding a new regenerative product to its portfolio in the field of sports medicine. To this end, the company has entered into a partnership with TissueRegenix in Italy for the distribution of OrthoPure® XT. This is a biomechanical tissue scaffold that restores quality of life to patients after cruciate ligament injuries.
April 05, 2022

The high-quality regenerative solution supports patients after sports injuries, because injuries to the anterior cruciate ligament are among the most common and at the same time the most serious knee injuries. They typically occur during twisting and jumping movements in sports. The immediate result is pain and instability in the anterior cruciate ligament, followed by damage to the meniscus and joint surfaces. The occurrence of osteoarthritis manifests itself in numerous cases over time.

Reach your goal easier, more efficiently and painlessly

What can OrthoPure® XT do better than conventional solutions? OrthoPure® XT eliminates the need for surgery at the donor site. Pain is reduced, faster recovery can be achieved. With an estimated 1.5 million reconstructions of the anterior cruciate ligament performed worldwide each year, this derives great potential. The product builds on its biomechanical tissue scaffold, which creates the conditions for cellular repopulation, potential regeneration. It is derived from animal tendon tissue, which is decellularized using Tissue Regenix's patented dCell® technology. OrthoPure® XT was launched in December 2020.

In-depth clinical research

The multi-year distribution agreement between Geistlich Biomaterials Italia and Tissue Regenix currently covers the Italian market, but also has the potential to expand to other markets. As part of the agreement, Geistlich has committed to drive clinical research around OrthoPure® XT to be conducted in some of the leading institutions and clinics in Italy. The scientific focus and dedication to regenerative solutions serving patients unites Geistlich Pharma with Tissue Regenix.

About Tissue Regenix

Tissue Regenix is a leading medical technology company in the field of regenerative medicine. The company's patented decellularization technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue. The result is an acellular tissue scaffold that is accepted by the patient's body. It can thus be used to repair diseased or damaged body structures. Typical fields of application are sports medicine, orthopedics and wound care.